Reproductive Complications and Sexual Dysfunction in Cancer Survivors

  • Leslie R. Schover


This chapter will review risk factors and management for three types of reproductive complications of cancer treatment: infertility, menopausal symptoms, and sexual dysfunction. Each problem area affects unique, albeit overlapping, populations of cancer patients and survivors.


Breast Cancer Cancer Survivor Erectile Dysfunction Sexual Function Breast Cancer Survivor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Lucas JW, Schiller JS, Benson V. Summary health statistics for United States adults: National Health Interview Survey, 2001. National Center for Health Statistics, Vital Health Stat 2004;10(218).Google Scholar
  2. 2.
    United States Census Bureau. US Summary 2000: Census 2000 Profile. Washington, DC: Government publication C2KPROF00US; 2002.Google Scholar
  3. 3.
    MacDorman MF, Minino AM, Strobino DM, et al. Annual summary of vital statistics—2001. Pediatrics 2002;110:1037–1052.PubMedGoogle Scholar
  4. 4.
    Bachu A, O’Connell M. Fertility of American women: June 2000. Current Population Reports, P20-543RV. U.S. Census Bureau, Washington, DC, 2001.Google Scholar
  5. 5.
    United Nations Population Division of the Department of Economic and Social Affairs. Wall chart: World Marriage Patterns 2000., accessed 12/7/04.Google Scholar
  6. 6.
    Jacobsen R, Bostofte E, Engholm G, et al. Fertility and offspring sex ratio of men who develop testicular cancer: a record linkage study. Hum Reprod 2000;15:1958–1961.PubMedGoogle Scholar
  7. 7.
    Skakkebæk NE, Rajpert-De Meyts E, Main KM. Testicular dysgenesis syndrome: an increasingly common developmental disorder with environmental aspects. Hum Reprod 2001;16:972–978.PubMedGoogle Scholar
  8. 8.
    Hoei-Hansen, CE, Holm M, Rajpert-De Meyts E, Skakkebæk NE. Histological evidence of testicular dysgenesis in contralateral biopsies from 218 patients with testicular germ cell cancer. J Pathol 2003;200:370–374.PubMedGoogle Scholar
  9. 9.
    Jacobsen R, Bostofte E., Engholm G, et al. Risk of testicular cancer in men with abnormal semen characteristics: cohort study. Brit Med J 2000;321:789–792.PubMedGoogle Scholar
  10. 10.
    Venn A, Healy D, McLachlan R. Cancer risks associated with the diagnosis of infertility. Best Practice & Res Clin Obstet Gynecol 2003;17:343–367.Google Scholar
  11. 11.
    Doyle P, Maconochie N, Beral V, et al. Cancer incidence following treatment for infertility at a clinic in the UK. Hum Reprod 2002;17:2209–2213.PubMedGoogle Scholar
  12. 12.
    Burkman RT, Tang MTC, Malone KE, et al. Infertility drugs and the risk of breast cancer: findings from the National Institute of Child Health and Human Development Women’s Contraceptive and Reproductive Experiences Study. Fertil Steril 2003;79:844–851.PubMedGoogle Scholar
  13. 13.
    Kauff ND, Satagopan JM, Robson ME, et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Eng J Med 2002;346:1609–1615.Google Scholar
  14. 14.
    Heidenreich A, Albers P, Hartmann M, et al. Complications of primary nerve sparing retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell tumors of the testis: experience of the German Testicular Cancer Study Group. J Urol 2003;169:1710–1714.PubMedGoogle Scholar
  15. 15.
    Havenga K, Maas CP, DeRuiter MC, Welvaart K, Trimbos JB. Avoiding long-term disturbance to bladder and sexual function in pelvic surgery, particularly with rectal cancer. Sem Surg Oncol 2000;18:235–243.Google Scholar
  16. 16.
    Meirow D, Nugent D. The effects of radiotherapy and chemotherapy on female reproduction. Hum Reprod 2001;7:535–543.Google Scholar
  17. 17.
    Tilly JL, Kolesnick RN. Sphingolipids, apoptosis, cancer treatments and the ovary: investigating a crime against female fertility. Biochim Biophys Acta 2002;1585:135–138.PubMedGoogle Scholar
  18. 18.
    Blumenfeld Z. Preservation of fertility and ovarian function and minimalization of chemotherapy associated gonadotoxicity and premature ovarian failure: the role of inhibin-A and-B as markers. Molecular Cellular Endocrinol 2002;187:93–105.Google Scholar
  19. 19.
    Minton SE, Munster PN. Chemotherapy-induced amenorrhea and fertility in women undergoing adjuvant treatment for breast cancer. Cancer Control 2002;9:466–472.PubMedGoogle Scholar
  20. 20.
    Thomson AB, Critchley HOD, Wallace WHB. Paediatric update: fertility and progeny. Eur J Cancer 2002;38:1634–1644.PubMedGoogle Scholar
  21. 21.
    Hassan MA, Killick SR. Effect of male age on fertility: evidence for the decline in male fertility with increasing age. Fertil Steril 2003;79(Suppl 3):1520–1527.PubMedGoogle Scholar
  22. 22.
    Schover LR, Rybicki LA, Martin BA, et al. Having children after cancer: a pilot survey of survivors’ attitudes and experiences. Cancer 1999;86:697–709.PubMedGoogle Scholar
  23. 23.
    Schover, LR Brey K, Lichtin A, et al. Knowledge and experience regarding cancer, infertility, and sperm banking in younger male survivors. J Clin Oncol 2002;20:1880–1889.PubMedGoogle Scholar
  24. 24.
    Green D, Galvin H, Horne B. The psycho-social impact of infertility on young male cancer survivors: a qualitative investigation. Psycho-Oncology 2003;12:141–152.PubMedGoogle Scholar
  25. 25.
    Thewes B, Meiser B, Rickard J, et al. The fertility-and menopause-related information needs of younger women with a diagnosis of breast cancer: a qualitative study. Psycho-Oncology 2003;12:500–511.PubMedGoogle Scholar
  26. 26.
    Dow KH. Having children after breast cancer. Cancer Practice 1994;2:407–413.PubMedGoogle Scholar
  27. 27.
    Stephen EH, Chandra A. Use of infertility services in the United States: 1995. Family Planning Perspect 2000;32:132–137.Google Scholar
  28. 28.
    Schover LR, Thomas AJ. Overcoming Male Infertility. New York: John Wiley & Sons, 2000.Google Scholar
  29. 29.
    Howell SJ, Shalet SM. Fertility preservation and management of gonadal failure associated with lymphoma therapy. Curr Oncol Rep 2002;4:443–452.PubMedGoogle Scholar
  30. 30.
    Kelnar CJ, McKinnell C, Walker M, et al. Testicular changes during infantile ‘quiescence’ in the marmoset and their gonadotrophin dependence: a model for investigating susceptibility of the prepubertal human testis to cancer therapy. Hum Reprod 2002;17:1367–1378PubMedGoogle Scholar
  31. 31.
    Blumenfeld Z, Dann E, Avivi R, et al. Fertility after treatment for Hodgkin’s disease. Ann Oncol 2002;13(Suppl 1):138–147.PubMedGoogle Scholar
  32. 32.
    Recchia F, Sica G, De Filippis S, et al. Goserelin as ovarian protection in the adjuvant treatment of premenopausal breast cancer: a phase II pilot study. Anti-Cancer Drugs 2002;13:417–424.PubMedGoogle Scholar
  33. 33.
    Familiari G, Caggiati, A, Nottola SA, et al. Ultrastructure of human ovarian primordial follicles after combination chemotherapy for Hodgkin’s disease. Hum Reprod 1993;8:2080–2087.PubMedGoogle Scholar
  34. 34.
    Tilly JL. Molecular and genetic basis of normal and toxicant-induced apoptosis in female germ cells. Toxicol Lett 1998;102–103:497–501.PubMedGoogle Scholar
  35. 35.
    Johnson J, Canning J, Kaneko T, Pru JK, Tilly J. Germline stem cells and follicular renewal in the postnatal mammalian ovary. Nature 2004;428:145–150.PubMedGoogle Scholar
  36. 36.
    Anger JT, Gilbert BR, Goldstein M. Cryopreservation of sperm: Indications, methods and results. J Urol 2003;170:1079–1084.PubMedGoogle Scholar
  37. 37.
    Agarwal A, Tolentine MV, Sidhu RS, et al. Effect of cryopreservation on semen quality of patients with testicular cancer. Urol 1995;46:382–389.PubMedGoogle Scholar
  38. 38.
    Padron OF, Sharma RK, Thomas AJ, et al. Effects of cancer on spermatozoa quality after cryopreservation: a 12-year experience. Fertil Steril 1997;67:326–331.PubMedGoogle Scholar
  39. 39.
    Lass A, Akagbosu F, Abusheikha N, et al. A programme of semen cryopreservation for patients with malignant disease in a tertiary infertility centre: lessons from 8 years’ experience. Hum Reprod 1998;13:3256–3261.PubMedGoogle Scholar
  40. 40.
    Audrins P, Holden CA, McLachlan RI, Kovacs GT. Semen storage for special purposes at Monash IVF from 1977 to 1997. Fertil Steril 1999;72:179–181.PubMedGoogle Scholar
  41. 41.
    Kelleher S, Wishart SM, Liu PY, et al. Long-term outcomes of elective human sperm cryostorage. Hum Reprod 2001;16:2632–2639.PubMedGoogle Scholar
  42. 42.
    Blackhall FH, Atkinson AD, Maaya MB et al. Semen cryopreservation, utilization and reproductive outcome in men treated for Hodgkin’s disease. Brit J Cancer 2002;87:381–384.PubMedGoogle Scholar
  43. 43.
    Agarwal A, Ranganathan P, Kattal N, et al. Fertility after cancer: a prospective review of assisted reproductive outcome with banked semen specimens. Fertil Steril 2004;81:342–348.PubMedGoogle Scholar
  44. 44.
    Ragni G, Somigliana E, Restelli L, et al. Sperm banking and rate of assisted reproduction treatment: insights from a 15-year cryopreservation program for male cancer patients. Cancer 2003;97:1624–1629.PubMedGoogle Scholar
  45. 45.
    Agarwal A, Sidhu RK, Shekarriz M, et al. Optimum abstinence time for cryopreservation of semen in cancer patients. J Urol 1995;54:86–88.Google Scholar
  46. 46.
    Hallak J, Sharma RK, Thomas AJ, et al. Why cancer patients request disposal of cryopreserved semen specimens posttherapy: a retrospective study. Fertil Steril 1998;69:889–893.PubMedGoogle Scholar
  47. 47.
    Schover LR, Brey K, Lichtin A, et al. Oncologists’ attitudes and practices regarding banking sperm before cancer treatment. J Clin Oncol 2002;20:1890–1897.PubMedGoogle Scholar
  48. 48.
    Wilford H, Hunt J. An overview of sperm cryopreservation services for adolescent cancer patients in the United Kingdom. Eur J Oncol Nurs 2003;7:24–32.PubMedGoogle Scholar
  49. 49.
    Allen C, Keane D, Harrison, RF. A survey of Irish consultants regarding awareness of sperm freezing and assisted reproduction. Ir Med J 2003;96:23–25.PubMedGoogle Scholar
  50. 50.
    Hallak J, Hendin B, Bahadur G, et al. Semen quality and cryopreservation in adolescent cancer patients. Hum Reprod 2002;17:3157–3161.Google Scholar
  51. 51.
    Nagano M, Patrizio P, Brinster RL. Long-term survival of human spermatogonial stem cells in mouse testes. Fertil Steril 2002;78:1225–1233.PubMedGoogle Scholar
  52. 52.
    Yoon TK, Kim TJ, Park SE, et al. Live births after vitrification of oocytes in a stimulated in vitro fertilization-embryo transfer program. Fertil Steril 2003;79:1323–1326.PubMedGoogle Scholar
  53. 53.
    Eroglu A, Toner M, Toth TL. Beneficial effect of microinjected trehalose on the cryosurvival of human oocytes. Fertil Steril 2002;77:152–158.PubMedGoogle Scholar
  54. 54.
    Gosden R, Nagano M. Preservation of fertility in nature and ART. Reprod 2002;123:3–11.Google Scholar
  55. 55.
    Liu J, Ju G, Qian Y, et al. Pregnancies and births achieved from in vitro matured oocytes retrieved from poor responders undergoing stimulation in in vitro fertilization cycles. Fertil Steril 2003;80:447–449.PubMedGoogle Scholar
  56. 56.
    Oktay K, Economos K, Khan M, et al. Endocrine function and oocyte retrieval after autologous transplantation of ovarian cortical strips to the forearm. JAMA 2001;286:1490–1493.PubMedGoogle Scholar
  57. 57.
    Radford JA, Leiberman BA, Brison RB, et al. Orthotopic reimplantation of cryopreserved ovarian cortical strips after high-dose chemotherapy for Hodgkin’s lymphoma. Lancet 2001;57:1172–1175.Google Scholar
  58. 58.
    Kim SS. Ovarian tissue banking for cancer patients: to do or not to do? Hum Reprod 2003;18:1759–1761.PubMedGoogle Scholar
  59. 59.
    Oktay K, Buyuk E, Veeck L, et al. Embryo development after heterotopic transplantation of cryopreserved ovarian tissue. Lancet 2004;363:837–840.PubMedGoogle Scholar
  60. 60.
    Lee DM, Yeoman RR, Battaglia DE, et al. Brief Communication: live birth after ovarian tissue transplant. Nature 2004;428:137–138.PubMedGoogle Scholar
  61. 61.
    Williams RS, Littell RD, Mendenhall NP. Laparoscopic oophoropexy and ovarian function in the treatment of Hodgkin disease. Cancer 1999;86:2138–2142.PubMedGoogle Scholar
  62. 62.
    Bisharah M, Tulandi T. Laparoscopic preservation of ovarian function: an underused procedure. Am J Obstet Gynecol 2003;188:367–370.PubMedGoogle Scholar
  63. 63.
    Picone O, Aucouturier JS, Louboutin A, et al. Abdominal wall metastasis of a cervical adenocarcinoma at the laparoscopic trocar insertion site after ovarian transposition: case report and review of the literature. Gynecol Oncol 2003;90:446–449.PubMedGoogle Scholar
  64. 64.
    Buekers TE, Anderson B, Sorosky JI, et al. Ovarian function after surgical treatment for ovarian cancer. Gynecol Oncol 2001;80:85–88.PubMedGoogle Scholar
  65. 65.
    Burnett AF, Roman LD, O’Meara AT, Morrow CP. Radical vaginal trachelectomy and pelvic lymphadenectomy for preservation of fertility in early cervical carcinoma. Gyn Oncol 2003;88:419–423.Google Scholar
  66. 66.
    Plante, M. Fertility preservation in the management of gynecologic cancers. Curr Opin Oncol 2000;12:497–507.PubMedGoogle Scholar
  67. 67.
    Schlaerth JB, Spritos NM, Schlaerth AC. Radical trachelectomy and pelvic lymphadenectomy with uterine preservation in the treatment of cervical cancer. Am J Obstet Gynecol 2003;188:29–34.PubMedGoogle Scholar
  68. 68.
    Shepherd JH, Mould T, Oram DH. Radical trachelectomy in early stage carcinoma of the cervix: outcome as judged by recurrence and fertility rates. BJOG 2001;108:882–885.PubMedGoogle Scholar
  69. 69.
    McHale MT, Le TD, Burger RA, et al. Fertility sparing treatment for in situ and early invasive adenocarcinoma of the cervix. Obstet Gynecol 2001;98:726–731.PubMedGoogle Scholar
  70. 70.
    Soutter WP, Haidopoulos D, Gornall, RJ, et al. Is conservative treatment for adenocarcinoma in situ of the cervix safe? BJOG 200l;108:1184–1189.Google Scholar
  71. 71.
    Morris RT, Gershenson DM, Silva EG, et al. Outcome and reproductive function after conservative surgery for borderline ovarian tumors. Obstet Gynecol 2000;95:541–547.PubMedGoogle Scholar
  72. 72.
    Brewer M, Gershenson DM, Herzog CE, et al. Outcome and reproductive function after chemotherapy for ovarian dysgerminoma. J Clin Oncol 1999;17:2670–2675.PubMedGoogle Scholar
  73. 73.
    Schilder JM, Thompson AM DePriest PD, et al. Outcome of reproductive age women with stage IA or IC invasive epithelial ovarian cancer treated with fertility-sparing therapy. Gynecol Oncol 2002;87:1–7.PubMedGoogle Scholar
  74. 74.
    Tangir J, Zelterman D, Ma W, Schwartz PE. Reproductive function after conservative surgery and chemotherapy for malignant germ cell tumors of the ovary. Obstet Gynecol 2003;101:251–257.PubMedGoogle Scholar
  75. 75.
    Meistrich ML, Wilson G, Mathur K, et al. Rapid recovery of spermatogenesis after mitoxantrone, vincristine, vinblastine, and prednisone chemotherapy for Hodgkin’s disease. J Clin Oncol 1997;15:3488–3495.PubMedGoogle Scholar
  76. 76.
    Ohl DA, Sonksen J. What are the chances of infertility and should sperm be banked? Sem Urol Oncol 1996;14:36–44.Google Scholar
  77. 77.
    Colombo R, Bertini R, Salonia A, et al. Nerve and seminal sparing radical cystectomy with orthotopic urinary diversion for select patients with superficial bladder cancer: an innovative surgical approach. J Urol 2001;165:51–55.PubMedGoogle Scholar
  78. 78.
    Weisz B, Schiff E, Lishner M. Cancer in pregnancy: maternal and fetal implications. Hum Reprod Update 2001;7:384–393.PubMedGoogle Scholar
  79. 79.
    Gwyn KM, Theriault RL. Breast cancer during pregnancy. Curr Treat Options Oncol 2000;1:239–243.PubMedGoogle Scholar
  80. 80.
    Schover LR. Psychosocial issues associated with cancer in pregnancy. Sem Oncol 2000;27:699–703.Google Scholar
  81. 81.
    Wenzel L, Berkowitz RS, Newlands E, et al. Quality of life after gestational trophoblastic disease. J Reprod Med 2002;47:387–394.PubMedGoogle Scholar
  82. 82.
    Green DM, Whitton JA, Stovall M, et al. Pregnancy outcome of female survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. Am J Obstet Gynecol 2002;187:1070–1080.PubMedGoogle Scholar
  83. 83.
    Critchley HO, Bath LE, Wallace WH. Radiation damage to the uterus: Review of the effects of treatment of childhood cancer. Hum Fertil 2002;5:61–66.Google Scholar
  84. 84.
    Surbone A, Petrek JA. Childbearing issues in breast carcinoma survivors. Cancer 1997;79:1271–1278.PubMedGoogle Scholar
  85. 85.
    Ginsburg ES, Yanushpolsky EH, Jackson KV. In vitro fertilization for cancer patients and survivors. Fertil Steril 2001;75:705–710.PubMedGoogle Scholar
  86. 86.
    Oktay KH, Buyuk E, Yermakova I, Veeck L, Rosenwaks Z. Fertility preservation in breast cancer patients: IVF and embryo cryopreservation after ovarian stimulation with tamoxifen. Hum Reprod 2003;18:90–95.PubMedGoogle Scholar
  87. 87.
    Oktay K. Further evidence on the safety and success of ovarian stimulation with letrozole and tamoxifen in breast cancer patients undergoing in vitro fertilization to cryopreserve their embryos for fertility preservation. J Clin Oncol 2005;23:3858–3859.PubMedGoogle Scholar
  88. 88.
    Anselmo AP, Cavalieri E, Aragona C, et al. Successful pregnancies following an egg donation program in women with previously treated Hodgkin’s disease. Haematologia 2001;86:624–628.Google Scholar
  89. 89.
    Larsen EC, Loft A, Holm K, et al. Oocyte donation in women cured of cancer with bone marrow transplantation including total body irradiation in adolescence. Hum Reprod 2000;15:1505–1508.PubMedGoogle Scholar
  90. 90.
    Giacalone PL, Laffargue F, Benos P, et al. Successful in vitro fertilization-surrogate pregnancy in a patient with ovarian transposition who had undergone chemotherapy and pelvic irradiation. Fertil Steril 2001;76:388–389.PubMedGoogle Scholar
  91. 91.
    Ohl DA, Denil J, Bennett CJ, et al. Electroejaculation following retroperitoneal lymphadenectomy. J Urol 1991;145:980–983.PubMedGoogle Scholar
  92. 92.
    Ohl DA, Wolf LJ, Menge AC, et al. Electroejaculation and assisted reproductive technologies in the treatment of anejaculatory infertility. Fertil Steril 2001;76:1249–1255.PubMedGoogle Scholar
  93. 93.
    Hovav Y, Dan-Goor M, Yaffe H, et al. Electroejaculation before chemotherapy in adolescents and young men with cancer. Fertil Steril 2001;75:811–813.PubMedGoogle Scholar
  94. 94.
    Damani MN, Master V, Meng MV, et al. Postchemotherapy ejaculatory azoospermia: fatherhood with sperm from testis tissue with intracytoplasmic sperm injection. J Clin Oncol 2002;20:930–936.PubMedGoogle Scholar
  95. 95.
    Chan PT, Palermo GD, Veeck LL, Rosenwaks Z, et al. Testicular sperm extraction combined with intracytoplasmic sperm injection in the treatment of men with persistent azoospermia postchemotherapy. Cancer 2001;92:1632–1637.PubMedGoogle Scholar
  96. 96.
    Robbins WA, Meistrich ML, Moore D, et al. Chemotherapy induces transient sex chromosomal and autosomal aneuploidy in human sperm. Nat Genet 1997;16:74–78.PubMedGoogle Scholar
  97. 97.
    Burrello N, Vicari E, Shin P, et al. Lower sperm aneuploidy frequency is associated with high pregnancy rates in ICSI programmes. Hum Reprod 2003;18:1371–1376.PubMedGoogle Scholar
  98. 98.
    Thomson AB, Campbell AJ, Irvine DC, et al. Semen quality and spermatozoal DNA integrity in survivors of childhood cancer: a case-control Study. Lancet 2002;360(9330):361–367.PubMedGoogle Scholar
  99. 99.
    Arnon J, Meirow D, Lewis-Roness H, et al. Genetic and teratogenic effects of cancer treatments on gametes and embryos. Hum Reprod 2001;7:394–403.Google Scholar
  100. 100.
    Winther JF, Boice JD, Mulvihill JJ, et al. Chromosomal abnormalities among offspring of childhood-cancer survivors in Denmark: a population-based study. Am J Hum Genet 2004;74:1282–1285.PubMedGoogle Scholar
  101. 101.
    Green DM, Whitton JA, Stovall M, et al. Pregnancy outcome of partners of male survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. J Clin Oncol 2003;21:716–721.PubMedGoogle Scholar
  102. 102.
    Sankila R, Olson JH, Anderson H, et al. Risk of cancer among offspring of childhood-cancer survivors. Association of the Nordic Cancer Registries and the Nordic Society of Paediatric Haematology and Oncology. N Engl J Med 1998;38:1339–1344.Google Scholar
  103. 103.
    Berry DL, Theriault RL, Holmes FA, et al. Management of breast cancer during pregnancy using a standardized protocol. J Clin Oncol 1999;7:855–861.Google Scholar
  104. 104.
    Narod SA. Hormonal prevention of hereditary breast cancer. Ann NY Acad Sci 2001;952:36–43.PubMedGoogle Scholar
  105. 105.
    Rebbeck TR, Lynch HT, Neuhausen SL, et al. The Prevention and Observation of Surgical End Points Study Group. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Eng J Med 2002;346:1616–1622.Google Scholar
  106. 106.
    Rechitsky S, Verlinsky O, Chistokhina A, et al. Preimplantation genetic diagnosis for cancer predisposition. Reprod Biomed 2002;5:148–155.Google Scholar
  107. 107.
    Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the United States: Prevalence and predictors. JAMA 1999;281:537–544.PubMedGoogle Scholar
  108. 108.
    Avis NE, McKinlay SM. The Massachusetts Women’s Health Study: an epidemiologic investigation of the menopause. J Amer Med Women’s Association 1995;50:45–49.Google Scholar
  109. 109.
    Avis NE, McKinlay SM. A longitudinal analysis of women’s attitudes toward the menopause: results from the Massachusetts Women’s Health Study. Maturitas 1991;13:65–79.PubMedGoogle Scholar
  110. 110.
    McKinlay JB, McKinlay SM, Brambilla DJ. Health status and utilization behavior associated with menopause. Amer J Epidemiol 1987;125:111–121.Google Scholar
  111. 111.
    Avis NE, Stellato R, Crawford S, Johannes C, et al. Is there an association between menopause status and sexual functioning? Menopause 2000;7:286–288.Google Scholar
  112. 112.
    McKinlay JB, McKinlay SM, Brambilla D. The relative contributions of endocrine changes and social circumstances to depression in mid-aged women. J Health Soc Behav 1987;28:345–363.PubMedGoogle Scholar
  113. 113.
    Avis NE, Crawford S, McKinlay SM. Psychosocial, behavioral, and health factors related to menopause symptomatology. Womens Health 1997;3:103–120.PubMedGoogle Scholar
  114. 114.
    Sternfeld B, Quesenberry CP Jr., Husson G. Habitual physical activity and menopausal symptoms: a case-control study. J Women’s Health 1999;8:115–123.Google Scholar
  115. 115.
    Keating NL, Cleary PD, Rossi AS, et al. Use of hormone replacement therapy by postmenopausal women in the United States. Annals Internal Med 1999;130:545–553.Google Scholar
  116. 116.
    Staropoli CA, Flaws JA, Bush TL, et al. Predictors of menopausal hot flashes. J Women’s Health 1998;7:1149–1155.Google Scholar
  117. 117.
    Carpenter JS, Johnson D, Wagner L, et al. Hot flashes and related outcomes in breast cancer survivors and matched comparison women. Oncol Nurs Forum 2002;29:E16–25.PubMedGoogle Scholar
  118. 118.
    Carpenter JS, Andrykowski MA, Cordova M, et al. Hot flashes in postmenopausal women treated for breast carcinoma: prevalence severity, correlates, management, and relation to quality of life. Cancer 1998;82:1682–1691.PubMedGoogle Scholar
  119. 119.
    Ganz PA, Rowland JH, Desmond K, et al. Life after breast cancer: understanding women’s health-related quality of life and sexual functioning. J Clin Oncol 1998;16:501–514.PubMedGoogle Scholar
  120. 120.
    Biglia N, Cozzarella M, Cacciari F, et al. Menopause after breast cancer: a survey on breast cancer survivors. Maturitas 2003;45:29–38.PubMedGoogle Scholar
  121. 121.
    Stein KD, Jacobsen PB, Hann DM, et al. Impact of hot flashes on quality of life among postmenopausal women being treated for breast cancer. Pain Symptom Manage 2000;19:436–445.Google Scholar
  122. 122.
    Nystedt M, Berglund G, Bolund C, et al. Side effects of adjuvant endocrine treatment in premenopausal breast cancer patients: a prospective randomized study. J Clin Oncol 2003;21:1836–1844.PubMedGoogle Scholar
  123. 123.
    Mourits MJ, Bockermann I, de Vries EG, et al. Tamoxifen effects on subjective and psychosexual well-being, in a randomized breast cancer study comparing high-dose and standard-dose chemotherapy. Br J Cancer 2002;86:1546–1550.PubMedGoogle Scholar
  124. 124.
    Ganz PA, Desmond KA, Leedham B, et al. Quality of life in long-term disease-free survivors of breast cancer: a follow-up study. J Natl Cancer Inst 2002;94:39–49.PubMedGoogle Scholar
  125. 125.
    Jensen PT, Klee MC, Groenvold M. Validation of a questionnaire for self-rating of urological and gynaecological morbidity after treatment of gynaecological cancer. Radiother Oncol 2002;65:29–38.PubMedGoogle Scholar
  126. 126.
    Denton AS, Maher EJ. Interventions for the physical aspects of sexual dysfunction in women following pelvic radiotherapy (Cochrane Review). In: The Cochrane Library 2003;3:1–26. Oxford: Update Software.Google Scholar
  127. 127.
    Schimmer AD, Quatermain M, Imrie D, et al. Ovarian function after autologous bone marrow transplantation. J Clin Oncol 1998;16:2359–2363.PubMedGoogle Scholar
  128. 128.
    Rossouw JE, Anderson GL, Prentice RL, et al. Risks and bene-fits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 2002;288:321–333.PubMedGoogle Scholar
  129. 129.
    Thompson CA, Shanafelt TD, Loprinzi CL. Andropause: symptom management for prostate cancer patients treated with hormonal ablation. The Oncologist 2003;8:474–487.PubMedGoogle Scholar
  130. 130.
    American Cancer Society. Cancer facts and figures: 2002. American Cancer Society, Atlanta, GA.Google Scholar
  131. 131.
    Smolin Y, Massie MJ. Male breast cancer: a review of the literature and a case report. Psychomatics 2002;43:326–330.Google Scholar
  132. 132.
    Hoda D, Perez DG, Loprinzi CL. Hot flashes in breast cancer survivors. Breast J 2003;9:431–438.PubMedGoogle Scholar
  133. 133.
    Ettinger B, Grady D, Tosteson ANA, et al. Effect of the Women’s Health Initiative on women’s decisions to discontinue postmenopausal hormone therapy. Obstet Gynecol 2003;102:1225–1232.PubMedGoogle Scholar
  134. 134.
    Beckmann MW, Jap D, Djahansouzi S, et al. Hormone replacement therapy after treatment of breast cancer: effects on postmenopausal symptoms, bone mineral density and recurrence rates. Oncol 2001;60:199–206.Google Scholar
  135. 135.
    Durna EM, Wren BG, Heller GZ, et al. Hormone replacement therapy after a diagnosis of breast cancer: cancer recurrence and mortality. Med J Australia 2002;177:347–351.PubMedGoogle Scholar
  136. 136.
    Decker DA, Pettinga JE, VanderVelde N, et al. Estrogen replacement therapy in breast cancer survivors: a matched-controlled series. Menopause 2003;10:277–285.PubMedGoogle Scholar
  137. 137.
    Wile AG, Opfell RW, Margileth DA. Hormone replacement therapy in previously treated breast cancer patients. Am J Surg 1993;165:372–375.PubMedGoogle Scholar
  138. 138.
    DiSaia PJ, Grosen EA, Kurosaki T, et al. Hormone replacement therapy in breast cancer survivors: a cohort study. Am J Obstet Gynecol 1996;174:1494–1498.PubMedGoogle Scholar
  139. 139.
    Dew J, Eden J, Beller E, et al. A cohort study of hormone replacement therapy given to women previously treated for breast cancer. Climacteric 1998;1:137–142.PubMedGoogle Scholar
  140. 140.
    Ursic-Vrscaj M, Bebar S. A case-control study of hormone replacement therapy after primary surgical breast cancer treatment. Eur J Surg Oncol 1999;25:146–151.PubMedGoogle Scholar
  141. 141.
    O’Meara ES, Rossing MA, Daling JR, et al. Hormone replacement therapy after a diagnosis of breast cancer in relation to recurrence and mortality. JNCI 2001;93:754–762.PubMedGoogle Scholar
  142. 142.
    Peters GN, Fodera T, Sabol J, et al. Estrogen replacement therapy after breast cancer: a 12-year follow-up. Ann Surg Oncol 2001;8:828–832.PubMedGoogle Scholar
  143. 143.
    Natrajan PK, Gambrell RD Jr. Estrogen replacement therapy in patients with early breast cancer. Am J Obstet Gynecol 2002;187:289–294.PubMedGoogle Scholar
  144. 144.
    Meurer LN, Lena S. Cancer recurrence and mortality in women using hormone replacement therapy after breast cancer: metaanalysis. J Fam Pract 2002;51:1056–1062.PubMedGoogle Scholar
  145. 145.
    Vassilopoulou-Sellin R, Cohen DS, Hortobagyi GN, et al. Estrogen replacement therapy for menopausal women with a history of breast carcinoma: results of a 5-year, prospective study. Cancer 2002;95:1817–1826.PubMedGoogle Scholar
  146. 146.
    Ganz PA, Greendale GA, Kahn B, et al. Are older breast carcinoma survivors willing to take hormone replacement therapy? Cancer 1999;86:814–820.PubMedGoogle Scholar
  147. 147.
    Holmberg L, Anderson H. The HABITS steering and data monitoring committee. Lancet 2004;363:453–455.PubMedGoogle Scholar
  148. 148.
    Quella SK, Loprinzi CL, Sloan JA, et al. Long term use of megestrol acetate by cancer survivors for the treatment of hot flashes. Cancer 1998;82:1784–1788.PubMedGoogle Scholar
  149. 149.
    Pandya KJ, Raubertas RF, Flynn PJ et al. Oral clonidine in postmenopausal patients with breast cancer experiencing tamoxifen-induced hot flashes: a University of Rochester Cancer Center Community Clinical Oncology Program study. Ann Inten Med 2000;32:788–793.Google Scholar
  150. 150.
    Stearns V, Beebe KL, Iyengar M, et al. Paroxetine controlled release in the treatment of menopausal hot flashes: a randomized controlled trial. JAMA 2003;289:2827–2834.PubMedGoogle Scholar
  151. 151.
    Loprinzi CL, Kugler JW, Sloan JA, et al. Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. Lancet 2000;356:2059–2063.PubMedGoogle Scholar
  152. 152.
    Quella SK, Loprinzi CL, Sloan J, et al. Pilot evaluation of venlafaxine for the treatment of hot flashes in men undergoing androgen ablation therapy for prostate cancer. J Urol 1999;162:98–102.PubMedGoogle Scholar
  153. 153.
    Quella SK, Loprinzi CL, Barton DL, et al. Evaluation of soy phytoestrogens for the treatment of hot flashes in breast cancer survivors: a North Center Cancer Treatment Group Trial. J Clin Oncol 2000;18:1068–1074.PubMedGoogle Scholar
  154. 154.
    Tice JA, Ettinger B, Ensrud K, et al. Phytoestrogen supplements for the treatment of hot flashes: the Isoflavone Clover Extract (ICE) Study: a randomized controlled trial. JAMA 2003;290:207–214.PubMedGoogle Scholar
  155. 155.
    Nikander E, Kilkkinen A, Metsa-Heikkila M, et al. A randomized placebo-controlled crossover trial with phytoestrogens in treatment of menopause in breast cancer patients. Obstet Gynecol 2003;101:1213–1220.PubMedGoogle Scholar
  156. 156.
    Muňoz GH, Pluchino S. Cimicifuga racemosa for the treatment of hot flushes in women surviving breast cancer. Maturitas 2003;44(Suppl 1):S59–65.Google Scholar
  157. 157.
    Wuttke W, Seidlove-Wuttke D, Gorkow C. The Cimicifuga preparation BNO 1055 vs. conjugated estrogens in a double-blind placebo-controlled study: effects on menopause symptoms and bone markers. Maturitas 2003;44(Suppl 1):S67–77.PubMedGoogle Scholar
  158. 158.
    Jacobson J, Traxel AB, Evans J, et al. Randomized trial of black cohosh for the treatment of hot flashes among women with a history of breast cancer. J Clin Oncol 2001;19:2739–2745.PubMedGoogle Scholar
  159. 159.
    Carpenter JS, Wells N, Lambert B, et al. A pilot study of magnetic therapy for hot flashes after breast cancer. Cancer Nurs 2002;25:104–109.PubMedGoogle Scholar
  160. 160.
    Porzio G, Trapasso T, Martelli S, et al. Acupuncture in the treatment of menopause-related symptoms in women taking tamoxifen. Tumori 2002;88:128–130.PubMedGoogle Scholar
  161. 161.
    Irvin JH, Domar AD, Clark C, et al. The effects of relaxation response training on menopausal symptoms. J Psychosom Obstet Gynaecol 1996;17:202–207.PubMedGoogle Scholar
  162. 162.
    Ivarsson T, Spetz AC, Hammar M. Physical exercise and vasomotor symptoms in postmenopausal women. Maturitas 1998;29:139–146.PubMedGoogle Scholar
  163. 163.
    Ganz PA, Greendale GA, Petersen L, et al. Managing menopausal symptoms in breast cancer survivors: Results of a randomized controlled trial. J Nat Cancer Inst 2000;92:1054–1064.PubMedGoogle Scholar
  164. 164.
    Rosen RC, Laumann EO. The prevalence of sexual problems in women: How valid are comparisons across studies? Arch Sex Behav 2003;32:209–211.PubMedGoogle Scholar
  165. 165.
    Laumann EO, Nicolosi A, Glasser DB, et al. GSSAB Investigators’ Group. Sexual problems among women and men aged 40–80 years: prevalence and correlates identified in the global study of sexual attitudes and behaviors. Int J Impot Res 2005;17:39–57.PubMedGoogle Scholar
  166. 166.
    Nicolosi A, Laumann EO, Glasser DB, et al. Global Study of Sexual Attitudes and Behaviors Investigators’ Group. Sexual behavior and sexual dysfunctions after age 40: the global study of sexual attitudes and behaviors. Urology 2004;64:991–997.PubMedGoogle Scholar
  167. 167.
    Feldman HA, Goldstein I, Hatzichristou DG, et al. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994;151:54–61.PubMedGoogle Scholar
  168. 168.
    Bacon CG, Mittleman MA, Kawachi I, et al. Sexual function in men older than 50 years of age: results from the Health Professionals Follow-Up Study. Ann Intern Med 2003;139:161–168.PubMedGoogle Scholar
  169. 169.
    Laumann EO, Gagnon JH, Michael RT, et al. The social organization of sexuality. Chicago: The University of Chicago Press, 1994:184–185.Google Scholar
  170. 170.
    Hollenbeck BK, Dunn RL, Wei JT, et al. Determinants of long-term sexual health outcome after radical prostatectomy measured by a validated instrument. J Urol 2003;169:1453–1457.PubMedGoogle Scholar
  171. 171.
    Andersen BL, Lachenbruch PA, Anderson B, et al. Sexual dysfunction and signs of gynecologic cancer. Cancer 1986;7:1880–1886.Google Scholar
  172. 172.
    Cooperberg MR, Koppie TM, Lubeck DP et al. How potent is potent? Evaluation of sexual function and bother in men who report potency after treatment for prostate cancer. Data from CaPSURE. Urol 2003;61:190–196.PubMedGoogle Scholar
  173. 173.
    Potosky AL, Davis WW, Hoffman RM, et al. Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the prostate cancer outcomes study. J Natl Cancer Inst 2004;96:1358–1367.PubMedGoogle Scholar
  174. 174.
    Steineck G, Helgesen F, Adolfsson J, et al. Quality of life after radical prostatectomy or watchful waiting. N Eng J Med 2002;347:790–796.Google Scholar
  175. 175.
    Schover LR, Fouladi RT, Warneke CL, et al. Defining sexual outcomes after treatment for localized prostate cancer. Cancer 2002;95:1773–1778.PubMedGoogle Scholar
  176. 176.
    Henningsohn L, Steven K, Kallestrup EB, et al. Distressful symptoms and well-being after radical cystectomy and orthotopic bladder substitution compared with a matched control population. J Urol 2002;168:168–175.PubMedGoogle Scholar
  177. 177.
    Havenga K, Maas CP, DeRuiter MC, Welvaart K, Trimbos JB. Avoiding long-term disturbance to bladder and sexual function in pelvic surgery, particularly with rectal cancer. Sem Surg Oncol 2000;18:235–243.Google Scholar
  178. 178.
    Jonker-Pool G, Van de Wile HBM, Hoekstra HJ, et al. Sexual functioning after treatment for testicular cancer: review and meta-analysis of 36 empirical studies between 1975–2000. Arch Sex Behav 2001;30:55–74.PubMedGoogle Scholar
  179. 179.
    Nazareth I, Lewin J, King M. Sexual dysfunction after treatment for testicular cancer: a systemic review. J Psychosom Res 2001;51:735–743.PubMedGoogle Scholar
  180. 180.
    Coogan CL, Hejase MJ, Wahle FR, et al. Nerve sparing post-chemotherapy retroperitoneal lymph node dissection for advanced testicular cancer. J Urol 1996;156:1656–1658.PubMedGoogle Scholar
  181. 181.
    Jacobsen KD, Ous S, Waehre H, et al. Ejaculation in testicular cancer patients after post-chemotherapy retroperitoneal lymph node dissection. Br J Cancer 1999;80:249–255.PubMedGoogle Scholar
  182. 182.
    Fossa SD, de Wit R, Roberts T, et al. Quality of life in good prognosis patients with metastatic germ cell cancer: a prospective study of the European Organization for Research and Treatment of Cancer Genitourinary Group/Medical Research Council Testicular Cancer study Group (30941/TE20). J Clin Oncol 2003;21:1107–1118.PubMedGoogle Scholar
  183. 183.
    Anatasiadis AG, Davis AR, Sawczuk IS, et al. Quality of life aspects in kidney cancer patients: data from a national registry. Supportive Care in Cancer 2003;11:700–706.Google Scholar
  184. 184.
    Syrjala KL, Roth-Roemer SL, Abrams JR, et al. Prevalence and predictors of sexual dysfunction in long-term survivors of marrow transplantation. J Clin Oncol 1998;16:3148–3157.PubMedGoogle Scholar
  185. 185.
    Dorval M, Maunsell E, Deschenes L, et al. Long-term quality of life after breast cancer: comparison of 8-year survivors with population controls. J Clin Oncol 1998;16:487–494.PubMedGoogle Scholar
  186. 186.
    Berglund G, Nystedt M, Bolund C, et al. Effect of endocrine treatment on sexuality in premenopausal breast cancer patients: a prospective randomized study. J Clin Oncol 2001;19:2788–2796.PubMedGoogle Scholar
  187. 187.
    Kornblith AB, Herndon JE II, Weiss RB, et al. Long-term adjustment of survivors of early-stage breast carcinoma, 20 years after adjuvant chemotherapy. Cancer 2003;98:679–689.PubMedGoogle Scholar
  188. 188.
    Schover LR, Yetman RJ, Tuason LJ, et al. Partial mastectomy and breast reconstruction: a comparison of their effects on psychosocial adjustment, body image, and sexuality. Cancer 1995;75:54–64.PubMedGoogle Scholar
  189. 189.
    Rowland JH, Desmond KA, Meyerowitz BE, et al. Role of breast reconstructive surgery in physical and emotional outcomes among breast cancer survivors. J Ntl Cancer Inst 2000;92:1422–1429.Google Scholar
  190. 190.
    Abrahamsen AF, Loge JH, Hannisdal E, et al. Socio-medical situation for long-term survivors of Hodgkin’s disease: a survey of 459 patients treated at one institution. Eur J Cancer 1998;34:1865–1870.PubMedGoogle Scholar
  191. 191.
    van Tulder MW, Aaronson NK, Bruning PF. The quality of life of long-term survivors of Hodgkin’s disease. Ann Oncol. 1994;5(2):153–158.PubMedGoogle Scholar
  192. 192.
    Kornblith AB, Anderson J, Cella DF, et al. Comparison of psychosocial adaptation and sexual function of survivors of advanced Hodgkin disease treated by MOPP, ABVD, or MOPP alternating with ABVD. Cancer 1992;15:2508–2516.Google Scholar
  193. 193.
    Bancroft J, Loftus J, Long JS. Distress about sex: a national survey of women in heterosexual relationships. Arch Sex Beh 2003;32:193–208.Google Scholar
  194. 194.
    Weijmar Schultz WCM, Van De Wiel HBM, Hahn DEE, et al. Psychosexual functioning after treatment for gynecological cancer: an integrative model, review of determinant factors and clinical guidelines. Int J Gynecol Cancer 1992;2:281–290.PubMedGoogle Scholar
  195. 195.
    Andersen BL, Anderson B, deProsse C. Controlled prospective longitudinal study of women with cancer: I. Sexual functioning outcomes. J Consult Clin Psychol. 1989;57:683–691.PubMedGoogle Scholar
  196. 196.
    Grumann M, Robertson R, Hacker NF, et al. Sexual functioning in patients following radical hysterectomy for stage IB cancer of the cervix. Int J Gynecol Cancer 2001;11:372–380.PubMedGoogle Scholar
  197. 197.
    Schover LR, Fife M, Gershenson DM. Sexual dysfunction and treatment for early stage cervical cancer. Cancer 1989;63:204–212.PubMedGoogle Scholar
  198. 198.
    Rhodes JC, Kjerulff KH, Langenberg PW, et al. Hysterectomy and sexual functioning. JAMA 1999;282:1934–1941.PubMedGoogle Scholar
  199. 199.
    Thakar R, Ayers S, Clarkson P, et al. Outcomes after total versus subtotal abdominal hysterectomy. N Engl J Med 2002;347:1318–1325.PubMedGoogle Scholar
  200. 200.
    Schover, LR, von Eschenbach, AC. Sexual function and female radical cystectomy: a case series. J Urol 1985;134:465–468.PubMedGoogle Scholar
  201. 201.
    Ratliff CR, Gershenson DM, Morris M, et al. Sexual adjustment in patients undergoing gracilis myocutaneous flap vaginal reconstruction in conjunction with pelvic exenteration. Cancer 1996;78:2229–2235.PubMedGoogle Scholar
  202. 202.
    Heiman JR. Sexual dysfunction: overview of prevalence, etiological factors, and treatments. J Sex Res 2002;39:73–78.PubMedGoogle Scholar
  203. 203.
    Schover LR, Evans RB, von Eschenbach AC. Sexual rehabilitation in a cancer center: diagnosis and outcome in 384 consultations. Arch Sex Beh 1987;16:445–461.Google Scholar
  204. 204.
    Moreira ED Jr, Brock G, Glasser DB, et al. GSSAB Investigators’ Group. Help-seeking behaviour for sexual problems: the global study of sexual attitudes and behaviors. Int J Clin Pract 2005;59:6–16.PubMedGoogle Scholar
  205. 205.
    Gingell C, Nicolosi A, Buvat J, et al. Preliminary results from the Global Study of Sexual Attitudes and Behaviors: patientphysician communication. Presented at the 18th Congress of the European Association of Urology, February 2002, Birmingham, UK.Google Scholar
  206. 206.
    Solursh DS, Ernst JL, Lewis RW, et al. The human sexuality education of physicians in North American medical schools. Int J Impot Res 2003;15(Suppl 5):S41–45.PubMedGoogle Scholar
  207. 207.
    Stead ML, Brown JM, Fallowfield L, et al. Lack of communication between healthcare professionals and women with ovarian cancer about sexual issues. Br J Cancer 2003;88:666–667.PubMedGoogle Scholar
  208. 208.
    Fossa SD, Woehre H, Kurth KH, et al. Influence of urological morbidity on quality of life in patients with prostate cancer. Eur Urol 1997;31(Suppl 3):S3–8.Google Scholar
  209. 209.
    Helgason AR, Adolfsson J, Dickman P, et al. Factors associated with waning sexual function among elderly men and prostate cancer patients. J Urol 1997;158:155–159.PubMedGoogle Scholar
  210. 210.
    Messing E. The timing of hormone therapy for men with asymptomatic advanced prostate cancer. Urol Oncol 2003;21:245–254.PubMedGoogle Scholar
  211. 211.
    Shahidi M, Norman AR, Gadd J, et al. Recovery of serum testosterone, LH and FSH levels following neoadjuvant hormone cytoreduction and radical radiotherapy in localized prostate cancer. Clin Oncol 2001;13:291–295.Google Scholar
  212. 212.
    Iversen P. Bicalutamide monotherapy for early stage prostate cancer: an update. J Urol 2003;170:S48–52.PubMedGoogle Scholar
  213. 213.
    Schover LR. Lesson 24: sexuality after pelvic cancer. AUA Updates, 2005.Google Scholar
  214. 214.
    Schover LR, Fouladi RT, Warneke CL, et al. Utilization of medical treatments for erectile dysfunction in prostate cancer survivors. Cancer 2002;95:2397–2407.PubMedGoogle Scholar
  215. 215.
    Merrick GS, Butler WM, Galbreath RW, et al. Erectile function after permanent prostate brachytherapy. Int J Radiation Oncology Biol Phys 2002;52:893–902.Google Scholar
  216. 216.
    Zietman AL, Sacco D, Skowronski U, et al. Organ conservation in invasive bladder cancer by transurethral resection, chemotherapy and radiation: results of a urodynamic and quality of life study on long-term survivors. J Urol 2003;170:1772–1776.PubMedGoogle Scholar
  217. 217.
    Bjerre BD, Johansen, C, Steven K. Sexological problems after cystectomy: bladder substitution compared with ileal conduit diversion. A questionnaire study of male patients. Scand J Urol Nephrol 1998;32:187–193.PubMedGoogle Scholar
  218. 218.
    Spitz A, Stein JP, Lieskovsky G, et al. Orthotopic urinary diversion with preservation of erectile and ejaculatory function in men requiring radical cystectomy for nonurothelial malignancy: a new technique. J Urol 1999;161:1761–1764.PubMedGoogle Scholar
  219. 219.
    Horenblas S, Meinhardt W, Ijzerman W, et al. Sexuality preserving cystectomy and neobladder: initial results. J Urol 2001;166:837–840.PubMedGoogle Scholar
  220. 220.
    Engel J, Kerr J, Schlesinger-Raab A, et al. Quality of life in rectal cancer patients: A four-year prospective study. Ann Surg 2003;238:203–213.PubMedGoogle Scholar
  221. 221.
    Chatterjee R, Kottaridis PD, McGarrigle HH, et al. Management of erectile dysfunction by combination therapy with testosterone and sildenafil in recipients of high-dose therapy for haematological malignancies. Bone Marrow Trans 2002;29:607–610.Google Scholar
  222. 222.
    Rajagopal A, Vassilopoulou-Sellin R, Palmer JL, et al. Hypogonadism and sexual dysfunction in male cancer survivors receiving chronic opioid therapy. J Pain Symptom Manage 2003;26:1055–1061.PubMedGoogle Scholar
  223. 223.
    Wang C, Swerdloff SR, Iranmanesh A, et al. Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. J Clin Endocrinol Metab 2000;85:2839–2853.PubMedGoogle Scholar
  224. 224.
    McNicholas TA, Mulder DH, Carnegie C, et al. A novel testosterone gel formulation normalizes androgen levels in hypogonadal men, with improvements in body composition and sexual function. BJU Int 2003;91:69–74.PubMedGoogle Scholar
  225. 225.
    Snyder PJ, Peachey H, Hannoush P, et al. Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age. J Clin Endocrinol Metab 1999;84:2647–2653.PubMedGoogle Scholar
  226. 226.
    Steidle C, Schwartz S, Jacoby K, et al. for the North American AA2500 T Gel Study Group. AA2500 testosterone gel normalizes androgen levels in aging males with improvements in body composition and sexual function. J Clin Endocrinol Metab 2003;88:2673–2681.PubMedGoogle Scholar
  227. 227.
    Aversa A, Isidori AM, Spera G, et al. Androgens improve cavernous vasodilation and response to sildenafil in patients with erectile dysfunction. Clin Endocrinol (Oxf) 2003;58:632–638.Google Scholar
  228. 228.
    Howell SJ, Radford JA, Adams JE, et al. Randomized placebocontrolled trial of testosterone replacement in men with mild Leydig cell insufficiency following cytotoxic chemotherapy. Clin Endocrinol (Oxf) 2001;55:315–324.Google Scholar
  229. 229.
    Kaplan HS. A neglected issue: the sexual side effects of current treatments for breast cancer. J Sex Marital Ther 1992;18:3–19.PubMedGoogle Scholar
  230. 230.
    Lillie EO, Bernstein L, Ursin G. The role of androgens and polymorphisms in the androgen receptor in the epidemiology of breast cancer. Breast Cancer Res 2003;5:164–173.PubMedGoogle Scholar
  231. 231.
    Padero MC, Bhasin S, Friedman TC. Androgen supplementation in older women: too much hype, not enough data. J Am Geriatr Soc 2002;50:1131–1140.PubMedGoogle Scholar
  232. 232.
    Cawood EHH, Bancroft J. Steroid hormones, the menopause, sexuality and well-being of women. Psychol Med 1996;26:925–936.PubMedGoogle Scholar
  233. 233.
    Bachmann GA, Leiblum SR, Kemmann E, et al. Sexual expression and its determinants in the post-menopausal woman. Maturitas 1984;6:19–29.PubMedGoogle Scholar
  234. 234.
    Dennerstein L, Dudley EC, Hoppel JL. Sexuality, hormones and the menopausal transition. Maturitas 1977;26:83–93.Google Scholar
  235. 235.
    Sherwin BB. Use of combined estrogen-androgen preparations in the postmenopause: evidence from clinical studies. Int J Fertil 1998;43:98–103.Google Scholar
  236. 236.
    Shifren JL, Braunstein GD, Simon JA, et al. Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. N Eng J Med 2000;343:682–688.Google Scholar
  237. 237.
    Floter A, Nathorst-Boos J, Carlsrom K, et al. Addition of testosterone to estrogen replacement therapy in oophorectomized women: effects on sexuality and well-being. Climacteric 2002;5:357–365.PubMedGoogle Scholar
  238. 238.
    van Leeuwen FE, Klokman WJ, Stovall M, et al. Roles of radiation dose, chemotherapy, and hormonal factors in breast cancer following Hodgkin’s disease. J Natl Cancer Inst 2003;95:971–980.PubMedGoogle Scholar
  239. 239.
    Laan E, van Lunsen RHW, Everaerd W. The effects of tibolone on vaginal blood flow, sexual desire and arousability in postmenopausal women. Climacteric 2001;4:28–41.PubMedGoogle Scholar
  240. 240.
    Stahlberg C, Tønnes Pedersen A, Lynge E, et al. Increased risk of breast cancer following different regimens of hormone replacement therapy frequently used in Europe. Int J Cancer 2004;109:721–727.PubMedGoogle Scholar
  241. 241.
    Hartmann U, Heiser K, Ruffer-Hesse C, et al. Female sexual desire disorders: subtypes, classification, personality factors and new directions for treatment. World J Urol 2002;20:79–88.PubMedGoogle Scholar
  242. 242.
    Andersen BL. Surviving cancer: the importance of sexual selfconcept. Med Pediatr Oncol 1999;33:15–23.PubMedGoogle Scholar
  243. 243.
    Schover LR, LoPiccolo J. Treatment effectiveness for dysfunctions of sexual desire. J Sex Marital Therapy 1982;8:179–197.Google Scholar
  244. 244.
    Hawton K, Catalan J, Fagg J. Low sexual desire: sex therapy results and prognostic factors. Behav Res Ther 1992;29:217–224.Google Scholar
  245. 245.
    Dewire DM, Todd E, Meyers P. Patient satisfaction with current impotence therapy. Wis Med J 1995;94:542–544.PubMedGoogle Scholar
  246. 246.
    Jarow JP, Nana-Sinkam P, Sabbagh M, et al. Outcome analysis of goal directed therapy for impotence. J Urol 1996;155:1609–1612.PubMedGoogle Scholar
  247. 247.
    Hanash KA. Comparative results of goal oriented therapy for erectile dysfunction. J Urol 1997;157:2135–2138.PubMedGoogle Scholar
  248. 248.
    El-Galley R, Rutland H, Talic R, et al. Long-term efficacy of sildenafil and tachyphylaxis effect. J Urol 2001;166:927–931.PubMedGoogle Scholar
  249. 249.
    Gonzalgo ML, Brotzman M, Trock et al. Clinical efficacy of sildenafil citrate and predictors of long-term response. J Urol 2003;170:503–506.PubMedGoogle Scholar
  250. 250.
    McCullough AR, Kau EL, Kaci L, et al. A 12-month longitudinal study of treatment seeking behavior in 200 men after radical retropubic prostatectomy. American Urological Association Abstracts (#1418), 2003.Google Scholar
  251. 251.
    Gontero P, Fontana F, Bagnasacco A, et al. Is there an optimal time for intracavernous Prostaglandin E1 rehabilitation following nonnerve sparing radical prostatectomy? Results from a hemodynamic prospective study. J Urol 2003;169:2166–2169.PubMedGoogle Scholar
  252. 252.
    Montorsi F, Guazzoni G, Strambi LF, et al. Recovery of spontaneous erectile function after nerve-sparing radical retropubic prostatectomy with and without early intracavernous injections of alprostadil: results of a prospective, randomized trial. J Urol 1997;158:1408–1410.PubMedGoogle Scholar
  253. 253.
    Brody S, Laan E, van Lunsen RH. Concordance between women’s physiological and subjective sexual arousal is associated with consistency of orgasm during intercourse but not other sexual behavior. J Sex Marital Ther 2003;29:15–23.PubMedGoogle Scholar
  254. 254.
    Modelska K, Cummings S. Female sexual dysfunction in postmenopausal women: Systematic review of placebo-controlled trials. Am J Obstet Gynecol 2003;188:286–293.PubMedGoogle Scholar
  255. 255.
    Berman JR, Berman LA, Toler SM, et al. Safety and efficacy of sildenafil citrate for the treatment of female sexual arousal disorder: a double-blind placebo-controlled study. J Urol 2003;170:2333–2338.PubMedGoogle Scholar
  256. 256.
    Padma-Nathan H, Brown C, Fendl J, et al. Efficacy and safety of topical alprostadil cream for the treatment of female sexual arousal disorder (FSAD): a double-blind, multicenter, randomized, and placebo-controlled clinical trial. J Sex Marital Ther 2003;29:329–344.PubMedGoogle Scholar
  257. 257.
    Ferguson DM, Steidle CP, Singh GS et al. Randomized, placebocontrolled, double blind, crossover design trial of the efficacy and safety of Zestra for Women in women with and without female sexual arousal disorder. J Sex Marital Ther 2003;29(Supple 1):33–44.PubMedGoogle Scholar
  258. 258.
    Basson R, McInnes R, Smith MD, et al. Efficacy and safety of sildenafil citrate in women with sexual dysfunction associated with female sexual arousal disorder. J Womens Health Gend Base Med 2002;11:367–377.Google Scholar
  259. 259.
    Mayor S. News roundup: Pfizer will not apply for a licence for sildenafil for women. BMJ 2004;328:542.PubMedGoogle Scholar
  260. 260.
    Wilson SK, Delk JR, Billups KL. Treating symptoms of female sexual arousal disorder with the Eros-Clitoral Therapy Device. J Gend Specif Med 2001;4:54–58.PubMedGoogle Scholar
  261. 261.
    Munarriz R, Maitland S, Garcia Sp, et al. A prospective duplex Doppler ultrasonographic study in women with sexual arousal disorder to objectively assess genital engorgement induced by EROS therapy. J Sex Marital Ther 2003;29(Suppl 1):85–94.PubMedGoogle Scholar
  262. 262.
    Bachmann G. Estradiol-releasing vaginal ring delivery system for urogenital atrophy. Experience over the past decade. J Reprod Med 1998;43:991–998.PubMedGoogle Scholar
  263. 263.
    Gabrielsson J, Wallen beck I, Birgerson L. Pharmacokinetic data on estradiol in light of the estring concept. Estradiol and estring pharmacokinetics. Acta Obstet Gynecol Scand Suppl 1996;163:26–34.PubMedGoogle Scholar
  264. 264.
    Buckler H, Al-Azzawi F for the UK VR Multicentre Trial Group. The effect of a novel vaginal ring delivering oestradiol acetate on climacteric symptoms in postmenopausal women. BJOG 2003;110:753–759.PubMedGoogle Scholar
  265. 265.
    Casper F, Petri E. Local treatment of urogenital atrophy with an estradiol-releasing vaginal ring: a comparative and a placebo-controlled multicenter study. Vaginal Ring Study Group. Int Urogynecol J & Pelvic Floor Dysfunct 1999;10:171–176.Google Scholar
  266. 266.
    Rioux JE, Devlin C, Gelfand MM, et al. 17beta-Estradiol vaginal tablet versus conjugated equine estrogen vaginal cream to relieve menopausal atrophic vaginitis. Menopause 2000;7:156–161.PubMedGoogle Scholar
  267. 267.
    Bruner DW, Lanciano R, Keegan M, et al. Vaginal stenosis and sexual function following intracavitary radiation for the treatment of cervical and endometrial carcinoma. Int J Radiat Oncol Biol Phys 1993;27:825–830.PubMedGoogle Scholar
  268. 268.
    Balleari E, Garre S, Van Lint MT, et al. Hormone replacement therapy and chronic graft-versus-host disease activity in women treated with bone marrow transplantation for hematologic malignancies. Ann N Y Acad Sci 2002;966:187–192.PubMedGoogle Scholar
  269. 269.
    Hayes EC, Rock JA. Treatment of vaginal agglutination associated with chronic graft-versus-host disease. Fertil Steril 2002;78:1125–1126.PubMedGoogle Scholar
  270. 270.
    Denton AS, Maher EJ. Interventions for the physical aspects of sexual dysfunction in women following pelvic radiotherapy. Cochrane Library 2003;3:1–26.Google Scholar
  271. 271.
    Robinson JW, Faris PD, Scott CB. Psychoeducational group increases vaginal dilation for younger women and reduced sexual fears for women of all ages with gynecological carcinoma treated with radiotherapy. Int J Radiation Oncology Biol Phys 1999;44:497–506.Google Scholar
  272. 272.
    Loprinzi CL, Abu-Ghazaleh S, Sloan JA, et al. Phase III randomized double-blind study to evaluate the efficacy of a polycarbophil-based vaginal moisturizer in women with breast cancer. J Clin Oncol 1997;15:969–973.PubMedGoogle Scholar
  273. 273.
    Nachtigall LE. Comparative study: replens versus local estrogen in menopausal women. Fertil Steril 1994;61:178–180.PubMedGoogle Scholar
  274. 274.
    Bygdemen M, Swahn ML. Replens versus dienoestrol cream in the symptomatic treatment of vaginal atrophy in postmenopausal women. Maturitas 1996;23:259–263.Google Scholar
  275. 275.
    Beji NK, Yalcin O, Erkan HA. The effect of pelvic floor training on sexual function of treated patients. Int Urogynecol J Pelvic Floor Dysfunct 2003;14:234–238.PubMedGoogle Scholar
  276. 276.
    Clemens JQ, Nadler RB, Schaeffer AJ, et al. Biofeedback, pelvic floor re-education, and bladder training for male chronic pelvic pain syndrome. Urol 2000;56:951–955.PubMedGoogle Scholar
  277. 277.
    Schover LR, von Eschenbach AC. Sexual and marital relationships after treatment for nonseminomatous testicular cancer. Urol 1985;25:251–255.PubMedGoogle Scholar
  278. 278.
    Sall M, Madsen FA, Rhodes PR, et al. Pelvic pain following radical retropubic prostatectomy: A prospective study. Urol 1997;49:575–579.PubMedGoogle Scholar
  279. 279.
    Masarani M, Cox R. The aetiology, pathophysiology and management of chronic orchialgia. BJU International 2003;91:435–437.PubMedGoogle Scholar
  280. 280.
    Schover LR. Sexuality and fertility after cancer. New York, John Wiley & Sons, 1997:122–130.Google Scholar
  281. 281.
    Padma-Nathan H. Diagnostic and treatment strategies for erectile dysfunction: the ‘Process of Care’ model. Int J Impot Res 2000;12(Suppl 4):S119–121PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  • Leslie R. Schover
    • 1
  1. 1.Department of Behavioral ScienceUniversity of Texas, M.D. Anderson Cancer CenterHoustonUSA

Personalised recommendations